The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

CTAG1B  -  cancer/testis antigen 1B

Homo sapiens

Synonyms: CT6.1, CTAG, CTAG1, ESO1, LAGE-2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CTAG1B


High impact information on CTAG1B


Chemical compound and disease context of CTAG1B


Biological context of CTAG1B


Anatomical context of CTAG1B

  • High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector [3].
  • In our study, NY-ESO-1 mRNA was found to express in 9.9% of the samples, and also correlated significantly with stages (P = 0.041) and local lymph node metastasis (P = 0.002) [2].
  • CTAG mRNA is expressed in a proportion of human cancers in a lineage-nonspecific fashion, whereas its expression in normal tissues is restricted to testis and ovary only [4].
  • Concurrently, a strong MHC class I-restricted CTL reactivity against the autologous NY-ESO-1-positive tumor cell line was found [7].
  • None of the 18 patients that tested seronegative for NY-ESO-1 had detectable CD4+ T cell responses [8].

Associations of CTAG1B with chemical compounds


Physical interactions of CTAG1B

  • In contrast, CD34-derived DCs were unable to process either soluble or immune complexed NY-ESO-1, although they efficiently presented preprocessed NY-ESO-1 peptides [14].
  • Both were specific for NY-ESO-1 because neither bound to homologous LAGE-1 peptides despite 84% overall amino acid homology [15].

Regulatory relationships of CTAG1B


Other interactions of CTAG1B


Analytical, diagnostic and therapeutic context of CTAG1B

  • To confirm the protein expression, immunohistochemistry was done for detecting the NY-ESO-1 antigen in mRNA-positive CRC tissues [2].
  • The presence of autologous antibodies against NY-ESO-1 was examined in serum samples by ELISA [2].
  • This expression pattern suggests that the CTAG product (NY-ESO-1) is an aberrantly activated tumor antigen and can potentially be an antigenic target for tumor vaccination [4].
  • NY-ESO-1 should therefore be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM [22].
  • Expression of NY-ESO-1 in EOC was demonstrated by RT-PCR and/or IHC in 82 of 190 (43%) specimens [23].


  1. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Hong, J.A., Kang, Y., Abdullaev, Z., Flanagan, P.T., Pack, S.D., Fischette, M.R., Adnani, M.T., Loukinov, D.I., Vatolin, S., Risinger, J.I., Custer, M., Chen, G.A., Zhao, M., Nguyen, D.M., Barrett, J.C., Lobanenkov, V.V., Schrump, D.S. Cancer Res. (2005) [Pubmed]
  2. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Li, M., Yuan, Y.H., Han, Y., Liu, Y.X., Yan, L., Wang, Y., Gu, J. Clin. Cancer Res. (2005) [Pubmed]
  3. High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. Batchu, R.B., Moreno, A.M., Szmania, S., Gupta, S.K., Zhan, F., Rosen, N., Kozlowski, M., Spencer, T., Spagnoli, G.C., Shaughnessy, J., Barlogie, B., Tricot, G., van Rhee, F. Hum. Gene Ther. (2003) [Pubmed]
  4. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Chen, Y.T., Boyer, A.D., Viars, C.S., Tsang, S., Old, L.J., Arden, K.C. Cytogenet. Cell Genet. (1997) [Pubmed]
  5. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. Jäger, E., Jäger, D., Karbach, J., Chen, Y.T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L.J., Knuth, A. J. Exp. Med. (2000) [Pubmed]
  6. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. Coral, S., Sigalotti, L., Colizzi, F., Spessotto, A., Nardi, G., Cortini, E., Pezzani, L., Fratta, E., Fonsatti, E., Di Giacomo, A.M., Nicotra, M.R., Natali, P.G., Altomonte, M., Maio, M. J. Cell. Physiol. (2006) [Pubmed]
  7. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Jäger, E., Chen, Y.T., Drijfhout, J.W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L.J., Knuth, A. J. Exp. Med. (1998) [Pubmed]
  8. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Gnjatic, S., Atanackovic, D., Jäger, E., Matsuo, M., Selvakumar, A., Altorki, N.K., Maki, R.G., Dupont, B., Ritter, G., Chen, Y.T., Knuth, A., Old, L.J. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  9. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Söling, A., Schurr, P., Berthold, F. Anticancer Res. (1999) [Pubmed]
  10. Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4. Minghetti, P.P., Ruffner, D.E., Kuang, W.J., Dennison, O.E., Hawkins, J.W., Beattie, W.G., Dugaiczyk, A. J. Biol. Chem. (1986) [Pubmed]
  11. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Romero, P., Dutoit, V., Rubio-Godoy, V., Liénard, D., Speiser, D., Guillaume, P., Servis, K., Rimoldi, D., Cerottini, J.C., Valmori, D. Clin. Cancer Res. (2001) [Pubmed]
  12. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Hasegawa, K., Noguchi, Y., Koizumi, F., Uenaka, A., Tanaka, M., Shimono, M., Nakamura, H., Shiku, H., Gnjatic, S., Murphy, R., Hiramatsu, Y., Old, L.J., Nakayama, E. Clin. Cancer Res. (2006) [Pubmed]
  13. Solution structure of a DNA complex with the fluorescent bis-intercalator TOTO determined by NMR spectroscopy. Spielmann, H.P., Wemmer, D.E., Jacobsen, J.P. Biochemistry (1995) [Pubmed]
  14. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Nagata, Y., Ono, S., Matsuo, M., Gnjatic, S., Valmori, D., Ritter, G., Garrett, W., Old, L.J., Mellman, I. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  15. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Vaughan, H.A., Svobodova, S., Macgregor, D., Sturrock, S., Jungbluth, A.A., Browning, J., Davis, I.D., Parente, P., Chen, Y.T., Stockert, E., St Clair, F., Old, L.J., Cebon, J. Clin. Cancer Res. (2004) [Pubmed]
  16. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. Goydos, J.S., Patel, M., Shih, W. J. Surg. Res. (2001) [Pubmed]
  17. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Chen, Q., Jackson, H., Parente, P., Luke, T., Rizkalla, M., Tai, T.Y., Zhu, H.C., Mifsud, N.A., Dimopoulos, N., Masterman, K.A., Hopkins, W., Goldie, H., Maraskovsky, E., Green, S., Miloradovic, L., McCluskey, J., Old, L.J., Davis, I.D., Cebon, J., Chen, W. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  18. Dendritic Cell Surface Calreticulin Is a Receptor for NY-ESO-1: Direct Interactions between Tumor-Associated Antigen and the Innate Immune System. Zeng, G., Aldridge, M.E., Tian, X., Seiler, D., Zhang, X., Jin, Y., Rao, J., Li, W., Chen, D., Langford, M.P., Duggan, C., Belldegrun, A.S., Dubinett, S.M. J. Immunol. (2006) [Pubmed]
  19. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Atanackovic, D., Arfsten, J., Cao, Y., Gnjatic, S., Schnieders, F., Bartels, K., Schilling, G., Faltz, C., Wolschke, C., Dierlamm, J., Ritter, G., Eiermann, T., Hossfeld, D.K., Zander, A.R., Jungbluth, A.A., Old, L.J., Bokemeyer, C., Kröger, N. Blood (2007) [Pubmed]
  20. Cancer-testis antigen expression in bladder cancer. Fradet, Y., Picard, V., Bergeron, A., LaRue, H. Prog. Urol. (2005) [Pubmed]
  21. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A.A., Frosina, D., Gnjatic, S., Ambrosone, C., Kepner, J., Odunsi, T., Ritter, G., Lele, S., Chen, Y.T., Ohtani, H., Old, L.J., Odunsi, K. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  22. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. van Rhee, F., Szmania, S.M., Zhan, F., Gupta, S.K., Pomtree, M., Lin, P., Batchu, R.B., Moreno, A., Spagnoli, G., Shaughnessy, J., Tricot, G. Blood (2005) [Pubmed]
  23. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Odunsi, K., Jungbluth, A.A., Stockert, E., Qian, F., Gnjatic, S., Tammela, J., Intengan, M., Beck, A., Keitz, B., Santiago, D., Williamson, B., Scanlan, M.J., Ritter, G., Chen, Y.T., Driscoll, D., Sood, A., Lele, S., Old, L.J. Cancer Res. (2003) [Pubmed]
WikiGenes - Universities